Please login to the form below

Not currently logged in
Email:
Password:

Parkinson's disease

This page shows the latest Parkinson's disease news and features for those working in and with pharma, biotech and healthcare.

Theranexus takes Alzheimer’s drug combo into clinic

Theranexus takes Alzheimer’s drug combo into clinic

Theranexus has been the green light to start trials of an Alzheimer’s disease therapy (AD) based on two generic medicines by the French authorities. ... It’s also testing the idea in two other combinations, THN102 (modafinil and flecainide) for

Latest news

More from news
Approximately 27 fully matching, plus 197 partially matching documents found.

Latest Intelligence

  • A quest for innovative solutions A quest for innovative solutions

    It is this quest for technology that can help patients with epilepsy and Parkinson’s, the sweet spots in its global operation that saw total revenue grow to 4.2bn in ... We have huge support to translate that change for both others in the organisation

  • Pfizer and IBM's tech-enabled 'Parkinson’s house' Pfizer and IBM's tech-enabled 'Parkinsons house'

    But this elegant home, surrounded by manicured lawns, is wired to beat the scourge of Parkinson’s disease. ... first patient for a Parkinson’s disease clinical trial.

  • Pharma deals continue to slide Pharma deals continue to slide

    an antibody for treatment of Parkinson’s disease. ... MEDI1341, an alpha-synuclein antibody entering phase I for treatment of Parkinson’s disease.

  • Erectile dysfunction, constipation, vaginal dryness and other laughing matters Erectile dysfunction, constipation, vaginal dryness and other laughing matters

    Normally there is a fear that a condition or disease might not be seen as credible. ... And on the Wednesday I got news that I had prostate cancer and Parkinson’s disease… But when we went into the living room I went, phrrhrht, ”he said, blowing a

  • Digital disruption Digital disruption

    Starting with projects in schizophrenia and Parkinson’s disease, Lundbeck and IBM will also work together to identify potential new drug targets and alternative indications. ... and chronic disease management, starting with respiratory and central

More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest appointments

  • Prevail Therapeutics adds to its board of directors Prevail Therapeutics adds to its board of directors

    The Prevail team has already made great progress in developing potential treatments for Parkinson’s disease and other neurodegenerative diseases, and I look forward to partnering with the team to help

  • Voyager Therapeutics appoints Matthew Ottmer as chief operating officer Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

    He said: “I am thrilled to join Voyager at this important time during the company’s evolution. ... Developing and implementing the initial commercial strategy and planning for VY-AADC for Parkinson’s disease is a top priority, especially as we

  • Newron Pharma appoints commercial affairs VP Newron Pharma appoints commercial affairs VP

    He brings sales and marketing experience from Johnson &Johnson, and served as franchise marketing director for psychiatry, Parkinson's disease and migraine products at Novartis. ... future. “ At the same time we welcome Dennis as a new member of

  • Voyager Therapeutics appoints chief financial officer Voyager Therapeutics appoints chief financial officer

    This strong foundation combined with the company's recent positive interim phase Ib data from its lead program VY-AADC01 for advanced Parkinson's disease and the opportunity to join a ... I am thrilled to join the Voyager team and meaningfully contribute

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... s disease, where we are working to

More from appointments
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest from PMHub

  • The dark side of direct-to-consumer genetic tests

    Instead, they interpret single-nucleotide polymorphisms (SNPs), and while SNPs can indicate a gene is associated with a disease, many are benign and have no impact on health. ... Who can blame them? If an email landed in your inbox that appeared to

  • The power of the patient

    The power of the patient. In this episode, we talk to Matt Eagles who was diagnosed with Parkinson's Disease aged just eight. ... He has also written a series of articles for Parkinson's UK in their Quarterly Journal.

  • Leading Edge expands their senior medical writing team

    of Oxford, where she studied the use of stem cells as an in-vitro model of Parkinson’ s disease.

  • Top 7 Trends in Pharma Marketing for 2015

    Wearable tech will play an even more integral role in the collection of aggregated patient data to help identify disease trends, predict treatment outcomes and improve future diagnoses. ... Indeed, early Jan 2015 news that  Genentech, a member of the

  • How can pharma help doctors in treating neurological disorders?

    How can pharma help doctors in treating neurological disorders? The large number of treatments that are now available to treat neurological disorders, such as multiple sclerosis (MS) and Parkinson’ s disease,

More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics